dsipar dsip- Injectable Peptide DSIP 2mg - Core Power

The second, semaglutide at the 2.4 mg dose, is the GLP-1 receptor agonist already established for weight management

( c ) Body weight time course, ( d ) change in body weight, fat mass (FM), and fat free mass (FFM) from day 5 to day 21

The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function

Orders placed before 2PM EST ship same-day via tracked delivery